BioCentury | Feb 10, 2014
Company News

InSite, Bess Royalty, SWK Holdings deal

...net sales of Besivance besifloxacin ophthalmic solution reaching undisclosed levels. Last April, InSite sold its royalty on Besivance...
...TSX:VRX; NYSE:VRX, Montreal, Quebec) acquired last August, and Pfizer Inc. (NYSE:PFE, New York, N.Y.) co-promote Besivance...
...million in Besivance royalty revenue in 2011 and $2.1 million in 2012. Patent expiration for Besivance...
BioCentury | Apr 8, 2013
Company News

InSite, Bausch + Lomb, Bess Royalty, SWK Holdings deal

...InSite sold its royalty on sales of Besivance besifloxacin ophthalmic solution to Bess Royalty and the SWK Funding...
...InSite's DuraSite delivery technology. Bausch + Lomb and Pfizer Inc. (NYSE:PFE, New York, N.Y.) co-promote Besivance...
...of the total purchase price from the royalty, InSite Vision will receive 25% of the Besivance...
BioCentury | Aug 15, 2011
Strategy

InSite's new vision

...about $430 million. In addition to AzaSite royalties from Merck, InSite receives single-digit royalties on Besivance...
...besifloxacin 0.06% ophthalmic suspension that uses DuraSite. Bausch + Lomb Inc. and Pfizer Inc. co-promote Besivance...
BioCentury | Jul 13, 2011
Financial News

InSite plans to raise $22.2 million

...solution marketed by the Inspire Pharmaceuticals Inc. subsidiary of Merck & Co. Inc. (NYSE:MRK); and Besivance...
BioCentury | Jun 8, 2009
Clinical News

Besivance besifloxacin ophthalmic solution regulatory update

...Bausch & Lomb said FDA approved an NDA for Besivance besifloxacin 0.06% ophthalmic suspension to treat...
...the U.S. (see BioCentury, March 9). Bausch & Lomb Inc. , Rochester, N.Y. Product: Besivance besifloxacin ophthalmic solution...
BioCentury | Dec 15, 2008
Clinical News

Besifloxacin ophthalmic solution regulatory update

...antimicrobial agent in the U.S. next year. Bausch & Lomb Inc. , Rochester, N.Y. Product: Besifloxacin ophthalmic solution...
BioCentury | Oct 27, 2008
Clinical News

Besifloxacin ophthalmic solution regulatory update

...Committee will meet on Dec. 5 to discuss an NDA from Bausch & Lomb for besifloxacin ophthalmic solution...
...conjunctivitis. Besifloxacin is a fluoroquinolone antimicrobial agent. Bausch & Lomb Inc. , Rochester, N.Y. Product: Besifloxacin ophthalmic solution...
BioCentury | Jan 5, 2004
Company News

InSite, Bausch & Lomb deal

...ISV sold to BOL its ISV-403 to treat ocular bacterial infections. ISV received a cash payment...
...the companies' 2002 deal, under which BOL received exclusive worldwide manufacturing and marketing rights to ISV-403...
...ISV for cancellation all the shares of ISV Series A-1 preferred stock from that deal. ISV-403...
BioCentury | May 5, 2003
Clinical News

ISV-403: Phase I

...in 48 healthy volunteers. The compound is partnered with BOL, which has exclusive rights to ISV-403...
...2000. InSite Vision Inc. (ISV), Alameda, Calif. Bausch & Lomb Inc. (BOL), Rochester, N.Y. Product: ISV-403...
BioCentury | Feb 17, 2003
Clinical News

ISV-403: Phase I

...ISV filed an IND to start Phase I trials of ISV-403 in the second quarter of...
...the filing, ISV will receive an equity investment from BOL, which has exclusive rights to ISV-403...
...2000. InSite Vision Inc. (ISV), Alameda, Calif. Bausch & Lomb Inc. (BOL), Rochester, N.Y. Product: ISV-403...
Items per page:
1 - 10 of 14